<DOC>
	<DOCNO>NCT02962401</DOCNO>
	<brief_summary>Prospective national multicenter open label phase II Remodel WM3 trial</brief_summary>
	<brief_title>Efficacity Idelalisib Obinutuzumab Patient With Relapsed Refractory Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>An Open Label non-randomized Phase II Study explore chemo-free treatment association Idelalisib Obinutuzumab Patient relapse refractory Waldenstrom 's Macroglobulinemia</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Age 18 year old Confirmed CD20 positive WM , accord recommendation 2nd Workshop WM . Presence least one criterion initiation therapy , accord 2nd Workshop WM . Recurrent fever , night sweat , weight loss , fatigue Hyperviscosity Lympadenopathy either symptomatic bulky equal 5cm maximum diameter Symptomatic hepatomegaly and/or splenomegaly Symptomatic organomegaly and/or organ tissue infiltration Peripheral neuropathy due WM Symptomatic cryoglobulinemia Cold agglutinin anemia Immune hemolytic anemia and/or thrombocytopenia Nephropathy relate WM Amyloidosis relate WM Hemoglobin less equal 10g dL Platelet count less 100 109 L Prior treatment WM comprise least one regimen contain therapeutic anti CD20 monoclonal antibody rituximab administer equal 2 dos antibody treatment therapeutic chemotherapy , alkylating agent , purine analogue , bendamustine administer equal 2 cycle treatment Patients may either relapse progress least 6 month last administration first line subsequent treatment refractory progress within 6 month first line subsequent treatment Number prior regimens per line 1 3 Life expectancy 3 month . ECOG le equal 2 . Meet follow pretreatment laboratory criterion screen visit conduct within 28 day study enrollment : ASAT 2.5 time upper limit institutional laboratory normal value . ALAT 2.5 time upper limit institutional laboratory normal value . Total bilirubin 1.5 time upper limit institutional laboratory normal value unless clearly related disease Gilbert syndrome Calculated measure creatinin clearance MDRD 40 mL minute . Premenopausal fertile female must agree use highly effective method birth control duration therapy 6 month end therapy . A highly effective method birth control define result low failure rate use consistently correctly implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomise partner . Men must agree father child duration therapy 6 month must agree advice female partner use highly effective method birth control . Voluntary write informed consent carry study related procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Prior treatment phosphatidylinositol 3 kinase PI3K inhibitor include idelalisib GA101 History anaphylactic reaction follow exposure humanize monoclonal antibody Previous allogeneic transplantation Treatment investigational agent participate another trial within 30 day prior enter study History malignancy chemotherapy radiotherapy neoplastic disease WM prior study . EXCEPTION : History malignancy except basal cell carcinoma skin , situ carcinoma breast cervix treat surgically curative intent , malignancy CR 5 year minimum , deemed appropriate inclusion trial per approval investigator Medical condition require longterm estimate one month use oral corticosteroid . Patients sign bacterial , viral fungal infection Preexisting hepatic enzyme elevation ASAT , ALAT CMV PCR antigenemia test positive Known history drug induce liver injury , chronic active hepatitis C HCV , chronic active hepatitis B HBV , alcoholic liver disease , nonalcoholic steatohepatitis , primary biliary cirrhosis , ongoing extrahepatic obstruction cause cholelithiasis , cirrhosis liver portal hypertension HIV antibody positive Positive HBV HBsAG surface positive HBC antibody Note : The tested negative eligible inclusion Preexisting pulmonary disease Known history drug induce pneumonitis Ongoing inflammatory bowel disease Women pregnant . Women breastfeed consent discontinue breastfeed Women childbearing age willing use effective anticonceptive method duration study 6 month end therapy Concurrent severe disease exclude administration therapy : Heart insufficiency NYHA grade III IV , LVEF &lt; 50 % RF &lt; 30 % , myocardial infarction within past 6 month prior study Severe chronic obstructive lung disease hypoxemia Severe diabetes mellitus Hypertension difficult control Cerebral dysfunction Richter 's syndrome Cardiac amyloidosis Any follow laboratory abnormality , related lymphoma : Absolute neutrophils count &lt; 1.5 x 109/L result bone marrow infiltration Platelet count &lt; 75 x 109/L result bone marrow infiltration . Central Nervous System involvement lymphoma Vaccination live vaccine within 28 day prior study entry Hypersensitivity active substance excipients list part 6.1 GAZYVARO ZYDELIG SmCP Serious medical psychiatric illness likely interfere participation clinical study . No consent registration , storage process individual diseasecharacteristics course well information family physician study participation Patient mental deficiency prevent proper understanding requirement treatment Person major law control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>